1 week Ago By Defense World Staff
Prudential Financial Inc. reduced its position in shares of Acelyrin, Inc. (NASDAQ:SLRN – Free Report) by 81.
6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,130 shares of the company’s stock after selling 62,600 shares during the period. Prudential Financial Inc.
’s holdings in Acelyrin were worth $44,000 at the end of the most recent quarter. A number of other hedge funds have also made changes to their positions in the company. American Century Companies Inc.
increased its position in shares of Acelyrin by 146.0% during the fourth quarter. American Century Companies Inc.
now owns 78,868 shares of the company’s stock worth $248,000 after purchasing an additional 46,802 shares in the last quarter. Intech Investment Management LLC boosted its stake in Acelyrin by 71.0% during the 4th quarter.
Intech Investment Management LLC now owns 26,587 shares of the company’s stock worth $83,000 after purchasing an additional 11,040 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Acelyrin by 36.
9% during the third quarter. Franklin Resources Inc. now owns 128,591 shares of the company’s stock worth $634,000 after buying an additional 34,642 shares in the last quarter.
Virtu Financial LLC acquired a new stake in shares of Acelyrin in the third quarter valued at about $50,000. Finally, Barclays PLC raised its position in shares of Acelyrin by 208.8% in the third quarter.
Barclays PLC now owns 96,408 shares of the company’s stock valued at $475,000 after buying an additional 65,188 shares during the last quarter. Institutional investors and hedge funds own 87.31% of the company’s stock.
Acelyrin Price PerformanceShares of SLRN stock opened at $2.23 on Friday. The firm’s 50-day moving average is $2.
43 and its two-hundred day moving average is $3.54. Acelyrin, Inc.
has a 12 month low of $1.85 and a 12 month high of $7.25.
The company has a market capitalization of $224.58 million, a PE ratio of -0.91 and a beta of 1.
12. Acelyrin (NASDAQ:SLRN – Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.
79) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.07.
Sell-side analysts forecast that Acelyrin, Inc. will post -2.53 EPS for the current year.
Wall Street Analyst Weigh InSLRN has been the subject of several research reports. Citigroup dropped their price objective on shares of Acelyrin from $6.00 to $3.
00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. HC Wainwright cut their price target on Acelyrin from $8.00 to $6.
00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.
com, Acelyrin currently has a consensus rating of “Hold” and a consensus target price of $9.60.Check Out Our Latest Stock Report on AcelyrinInsider Buying and Selling at AcelyrinIn other news, CEO Mina Kim sold 17,986 shares of the firm’s stock in a transaction that occurred on Monday, March 17th.
The shares were sold at an average price of $2.74, for a total value of $49,281.64.
Following the completion of the transaction, the chief executive officer now owns 671,753 shares of the company’s stock, valued at approximately $1,840,603.22. This trade represents a 2.
61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 13.
60% of the stock is currently owned by corporate insiders. Acelyrin Profile (Free Report)Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Recommended StoriesFive stocks we like better than AcelyrinWhat is the Dogs of the Dow Strategy? Overview and ExamplesJPMorgan is a Buy, if You Can Handle The Volatility How to trade penny stocks: A step-by-step guideUnited States Steel’s Crash: An Unmissable Buying OpportunityStock Analyst Ratings and Canadian Analyst RatingsRocket Lab Stock: Weathering the Storm, Time for a Comeback?.
